AbbVie (ABBV) Company Report

US rheumatologists are shifting from broad enthusiasm to more selective, indication-driven expectations for late-stage SLE assets, concentrating interest on a narrower set of perceived leaders.
Gazyva (obinutuzumab), Rinvoq (upadacitinib), and ianalumab emerge as top late-stage contenders, with Gazyva’s recent lupus nephritis approval expected to reshape treatment pathways, notably in patients with renal involvement.
Physicians estimate that around 17–20% of moderate-to-severe SLE patients would be appropriate candidates for these leading therapies, reflecting a targeted deployment strategy.
Interest has moderated for other mid-to-late-stage assets—litifilimab and dapirolizumab pegol face safety and durability concerns, while cenerimod is viewed as a niche oral option.

Jan 20, 2026, 2:17 PM

Press Release

AbbVie announces Phase 3 EPCORE DLBCL-1 topline results

ABBV

Epcoritamab showed improved progression-free survival versus investigator’s choice chemoimmunotherapy in relapsed/refractory DLBCL (PFS HR 0.74 [95% CI 0.60–0.92]).
The study enrolled 483 patients ineligible for high-dose chemo and stem cell transplant, with benefits in complete response rate, duration of response, and time to next treatment.
No statistically significant overall survival benefit was observed (OS HR 0.96 [95% CI 0.77–1.20]).
AbbVie and Genmab will engage global regulators on next steps and present full data at future medical meetings.

Jan 16, 2026, 6:43 PM

Press Release

AbbVie outlines 2026 priorities and pipeline at J.P. Morgan Healthcare Conference

ABBV

Guidance Update

Product Launch

2026 priorities: focus on operational execution to sustain financial momentum and advance pipeline with expected approvals for Vyalev and Tavapadon, indication expansions for Rinvoq, Ubrelvy, Qulipta, and pivotal data for Lutikizumab and Itentamig.
Financial outlook: reaffirmed target of high single-digit CAGR through the decade; 2025 top-line grew ~8% with the growth platform expanding ~19%; EPS to outpace revenue via margin expansion and ~~15% R&D spend (~~$9 billion).
Immunology: maintain 2027 guidance of $31 billion combined sales for Skyrizi ($20 billion) and Rinvoq ($11 billion), driven by head-to-head trials, market share gains, and low single-digit pricing headwinds.
Neuroscience & oncology: neuroscience fastest growing segment aiming to be industry leader with Vyalev at ~$450 million in first full year and Tavapadon launch; oncology pipeline advancing ADCs Umbrellas and Teliso, with phase III start for SEZ6-targeting ADC and Itentamig monotherapy ORR readout.
Aesthetics: investing in consumer outreach to revitalize Botox and filler demand and preparing to launch Trinibot E (short-acting toxin) globally in H2 2026 to lower trial barriers and drive cash-pay growth.

Jan 14, 2026, 4:15 PM

Transcript

AbbVie outlines 2026 strategy and pipeline at JP Morgan Healthcare Conference

ABBV

Guidance Update

Product Launch

New Projects/Investments

2026 strategic priorities: deliver strong financial results, maintain high-single-digit CAGR through the decade, and advance pipeline with upcoming approvals for Vyalev, Tavapadon, Lutikizumab, and Itentamig.
Immunology: ex-Humira growth platform expanded by $15 billion over 2023–25 and grew ~19% in 2025; Skyrizi and Rinvoq pipeline includes new indications in giant cell arteritis, lupus, alopecia areata, vitiligo, and hidradenitis suppurativa.
Neuroscience: fastest-growing franchise, on track to be the largest globally; Vyalev posted $450 million in 2025 first-full-year sales and Tavapadon is set to launch late 2026; pipeline also features Gemibot for essential tremor and next-gen psychiatry assets (932, kappa opioid antagonists, Emraclidine, Bradacillisin).
Oncology: evolving solid-tumor ADC portfolio with c-Met ADCs Umbrella s and Teliso, initiating phase 3 trials in colorectal, lung (EGFR wild-type/mutant), pancreatic, and SCLC; Itentamig phase 3 in hematologic malignancies could read out ORR in 2026.
Aesthetics: investing in consumer marketing to revitalize Botox and HA filler markets amid softness, maintaining category leadership, and planning global launch of Trinibot E (short-acting toxin) in H2 2026.

Jan 14, 2026, 4:15 PM

Transcript

AbbVie outlines 2026 strategic priorities at J.P. Morgan Healthcare Conference

ABBV

In 2025, total company sales grew approximately 8% while the ex-Humira growth platform rose 19%, underpinning AbbVie’s goal of high single-digit revenue CAGR through the 2030s as R&D spending remains near 15% of sales.
Immunology leaders Skyrizi and Rinvoq have collectively added $15 billion in sales since 2023 and are guided to reach $31 billion combined by 2027 (Skyrizi $20 billion; Rinvoq $11 billion) with further indication expansions planned.
Key pipeline milestones over the next two years include FDA filings/approvals for Vyalev and Tavapadon, indication expansions for Skyrizi, Rinvoq, Ubrelvy, Qulipta, and pivotal data readouts for lutikizumab and itentamig.
Neuroscience, AbbVie’s second-largest and fastest-growing segment, is on track to become the industry’s largest with Vyalev targeting $450 million in first-year sales and Tavapadon launching late 2026, alongside late-stage programs in Parkinson’s, psychiatry, and migraine.
Management expects low single-digit pricing headwinds in immunology and is maintaining strategic investments in aesthetics (Botox/fillers) amid macro softness, including consumer campaigns and the planned H2 2026 launch of Trinibot E.

Jan 14, 2026, 4:15 PM

Transcript

AbbVie strikes drug-pricing deal with Trump administration

ABBV

New Projects/Investments

AbbVie reached a voluntary three-year agreement with the Trump administration to offer lower Medicaid prices and sell drugs directly via the TrumpRx platform, committing $100 billion to U.S. R&D, development and manufacturing over the next decade.
The pact covers key drugs including Humira, Synthroid, Combigan and Alphagan, with “Most Favored Nation” or deep-discount pricing in exchange for tariff exemptions and relief from future pricing mandates.
AbbVie’s scale: $389 billion market capitalization; $59.6 billion revenue (past 12 months); ~29,000 U.S. employees; medicines used by ~16 million Americans annually.
This deal is one of over a dozen similar pacts under the administration’s pricing initiative, alongside agreements with Amgen, Bristol Myers Squibb, Merck and others.

Jan 13, 2026, 1:17 AM

WSJ

AbbVie reaches drug pricing agreement with Trump administration

ABBV

New Projects/Investments

AbbVie entered a three-year voluntary agreement with the Trump administration to improve drug access and affordability, securing exemptions from tariffs and future pricing mandates.
The company will offer low Medicaid prices and expand direct-to-patient offerings via TrumpRx for medicines such as HUMIRA, SYNTHROID, ALPHAGAN and COMBIGAN.
AbbVie commits $100 billion in U.S.-based R&D and capital investments, including manufacturing, over the next decade.

Jan 12, 2026, 11:30 PM

Press Release

AbbVie inks licensing deal with RemeGen for novel bispecific oncology antibody

ABBV

New Projects/Investments

AbbVie secured exclusive rights to develop, manufacture and commercialize RC148, a PD-1/VEGF bispecific antibody for advanced solid tumors, outside the Greater China territory.
RC148 combines immune checkpoint inhibition and anti-angiogenic activity, showing early favorable antitumor activity and potential for combination with AbbVie’s ADCs such as investigational Temab-A.
Under the agreement, RemeGen receives a $650 million upfront payment and may earn up to $4.95 billion in development, regulatory, and commercial milestones, plus tiered double-digit royalties.
The collaboration reinforces AbbVie’s commitment to expand its oncology portfolio through strategic partnerships and multispecific antibody platforms.

Jan 12, 2026, 12:30 PM

Press Release

AbbVie acquires Arizona manufacturing facility

ABBV

M&A

New Projects/Investments

AbbVie will acquire a device manufacturing site in Tempe, Arizona, plus associated IP for 3.5 mL on-body injector technology, from West Pharmaceutical Services.
The transaction, expected to close in mid-2026, includes a $175 million investment and the hiring of ~200 employees at the facility.
This acquisition supports AbbVie's plan to invest over $10 billion in U.S. manufacturing capacity and innovation over the next decade.
Once completed, AbbVie’s U.S. manufacturing footprint will expand beyond its 11 sites and nearly 29,000 employees nationwide.

Jan 12, 2026, 11:00 AM

Press Release

Cartesian Therapeutics outlines 2026 outlook

ABBV

Enrollment is on track in the Phase 3 AURORA trial of Descartes-08 for myasthenia gravis, with ~100 AChR Ab+ participants receiving six once-weekly outpatient infusions vs placebo and a primary endpoint of ≥3-point MG-ADL improvement at Month 4.
The FDA accepted the IND for the seamless adaptive Phase 2 TRITON trial in myositis, set to begin in 1H 2026, with an interim analysis after 10 participants to inform a potential single pivotal trial.
A Phase 1/2 (HELIOS) pediatric trial of Descartes-08 in juvenile dermatomyositis and other pediatric autoimmune diseases has been initiated.
Two Nature Medicine publications detailed Descartes-08’s mechanism and reported that in Phase 2b MG patients, 57% of biologic-naïve participants achieved minimal symptom expression by Month 6 through Month 12 and the median prednisone dose was reduced by 55% at Month 12 with no CRS or ICANS observed.
Current cash resources are expected to support ongoing operations, including completion of the Phase 3 AURORA and initiation of the Phase 2 myositis trials, into mid-2027.